Results 251 to 260 of about 41,710 (302)

Economic burden of type 2 diabetes management in France according to clinical characteristics

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4019-4032, May 2026.
Abstract Aim We sought to investigate the treatment, medication patterns, and economic burden of type 2 diabetes (T2D) in France. Materials and Methods This was a descriptive retrospective cross‐sectional study of a representative sample of adults in the national healthcare system claims database in 2022.
Bruno Guerci, Christèle Blanc‐Bisson, Eric Vicaut, Gérard De Pouvourville, Bruno Detournay, Corinne Emery, Isabelle Bureau, Taos Ihaddadene‐Salzgeber, Fleur Levrat‐Guillen, Jean‐Pierre Riveline   +9 more
wiley   +1 more source

Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. [PDF]

Endocrinol Metab (Seoul)
Kamrul-Hasan ABM, Alam MS, Talukder SK, Dutta D, Selim S.   +4 more
europepmc   +1 more source

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis [PDF]

core   +1 more source

Impact of specialised endocrinology care on metabolic control and healthcare utilisation outcomes after kidney transplantation in patients with diabetes: A 12‐month observational cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4082-4090, May 2026.
Abstract Aims To evaluate whether an endocrinology‐integrated transplant clinic and differing healthcare delivery models are associated with metabolic outcomes during the first year after kidney transplantation in recipients with pre‐existing diabetes.
Joaquin Lado‐Abeal, Francisco Gude, Maria Jose Ginzo‐Villamayor, Khalid Al‐Zubaidi, Jacqueline C. Stocking, Gemma Rodriguez‐Carnero, Aili Guo, Prasanth Surampudi, Caroline Lenaerts, Vedesh K. Babu, Deborah Plante, Yihung Huang, Antia Fernandez‐Pombo   +12 more
wiley   +1 more source

Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4112-4120, May 2026.
ABSTRACT Aims Evogliptin, a dipeptidyl peptidase‐4 inhibitor with a glucose‐dependent mechanism of action, is widely used as a monotherapy or in combination with other agents. However, observational studies in routine clinical settings remain limited.
Jun Hwa Hong, Sung Hoon Yu, Ki‐Hyun Baek, JaeMyung Yu, Seung Jin Lee, Hyung‐Wook Kim, Kang Seo Park, Jung Han Kim, KyungWan Min, Yong Hwan Lee, Koon Soon Kim, Min Soo Song, Ji Hoon Kim, Jie‐Eun Lee, Jong Chul Won   +14 more
wiley   +1 more source

Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer

Clinical Endocrinology, Volume 104, Issue 5, Page 507-509, May 2026.
Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert, The UK Thyroid Cancer Study Group   +4 more
wiley   +1 more source

Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4314-4325, May 2026.
ABSTRACT Aims To compare the effects of individual SGLT2 inhibitors on preventing new‐onset proteinuria in patients with type 2 diabetes and preserved kidney function. Materials and Methods A target trial emulation was performed using commercially available databases, including health checkups and claims data, between April 1, 2014 and March 31, 2023 ...
Hiroki Nobayashi, Michihiro Satoh, Takuo Hirose, Shingo Nakayama, Yutaro Iwabe, Hideaki Hashimoto, Takahisa Murakami, Kouji Okada, Takefumi Mori, Hirohito Metoki   +9 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dipeptidyl peptidase-4 inhibitors

Reactions Weekly, 2021
The dipeptidyl peptidase 4 (DPP-4) inhibitor has become a popular anti-diabetes medication since its introduction in 2006. They are small molecules that specifically bind to the catalytic domain of DPP-4, which consequently prevents the enzymatic inactivation of incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide)
Yoo Hyung Kim, Young Min Cho
openaire   +2 more sources

Renal outcomes with dipeptidyl peptidase-4 inhibitors

Diabetes & Metabolism, 2018
Dipeptidyl peptidase-4 inhibitors (DPP-4is) are increasingly being used in the management of type 2 diabetes (T2D). The present review summarizes the current knowledge of the effects of DPP-4is on renal outcomes by analyzing the experimental preclinical data, the effects of DPP-4is on urinary albumin-creatinine ratios (UACRs) and estimated glomerular ...
Scheen, André, DELANAYE, Pierre
openaire   +3 more sources

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

Drugs, 2011
The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of endogenously released incretin hormones, represent a new therapeutic approach to the management of type 2 diabetes mellitus. The 'first-in-class' DPP-4 inhibitor, sitagliptin, was approved in
R. Baetta, A. Corsini
openaire   +2 more sources